TR201820076T4 - İlaç kombinasyonlarının salımı. - Google Patents
İlaç kombinasyonlarının salımı. Download PDFInfo
- Publication number
- TR201820076T4 TR201820076T4 TR2018/20076T TR201820076T TR201820076T4 TR 201820076 T4 TR201820076 T4 TR 201820076T4 TR 2018/20076 T TR2018/20076 T TR 2018/20076T TR 201820076 T TR201820076 T TR 201820076T TR 201820076 T4 TR201820076 T4 TR 201820076T4
- Authority
- TR
- Turkey
- Prior art keywords
- doxorubicin
- microspheres
- irinotecan
- ibuprofen
- polymer matrix
- Prior art date
Links
- 239000000890 drug combination Substances 0.000 title 1
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 abstract 6
- 239000004005 microsphere Substances 0.000 abstract 4
- 229960004679 doxorubicin Drugs 0.000 abstract 3
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 229960001680 ibuprofen Drugs 0.000 abstract 2
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 abstract 2
- 229960004768 irinotecan Drugs 0.000 abstract 2
- 239000011159 matrix material Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 229920000642 polymer Polymers 0.000 abstract 2
- 239000004372 Polyvinyl alcohol Substances 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 230000010109 chemoembolization Effects 0.000 abstract 1
- 230000000295 complement effect Effects 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000008177 pharmaceutical agent Substances 0.000 abstract 1
- 229920002451 polyvinyl alcohol Polymers 0.000 abstract 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 abstract 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 abstract 1
- 229960002930 sirolimus Drugs 0.000 abstract 1
- 230000002195 synergetic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB0716003A GB0716003D0 (en) | 2007-08-16 | 2007-08-16 | Delivery of drug combinations |
| EP07121158 | 2007-11-20 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201820076T4 true TR201820076T4 (tr) | 2019-01-21 |
Family
ID=39941549
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2018/20076T TR201820076T4 (tr) | 2007-08-16 | 2008-08-18 | İlaç kombinasyonlarının salımı. |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20110229572A1 (https=) |
| EP (1) | EP2190409B9 (https=) |
| JP (3) | JP2010536738A (https=) |
| ES (1) | ES2706023T3 (https=) |
| TR (1) | TR201820076T4 (https=) |
| WO (1) | WO2009022190A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1985286A1 (en) * | 2007-04-24 | 2008-10-29 | Biocompatibles UK Limited | Microspheres for treatment of brain tumours |
| US20140378404A1 (en) * | 2011-10-25 | 2014-12-25 | Nektar Therapeutics | Treatment of Patients Suffering from Cancer |
| WO2015134837A2 (en) * | 2014-03-06 | 2015-09-11 | University Of Southern California | Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues |
| ES2913851T3 (es) * | 2018-02-23 | 2022-06-06 | Van Rijn Beheer B V | Microesferas de embolización porosas que comprenden fármacos |
| JP2022502531A (ja) | 2018-10-12 | 2022-01-11 | ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイションUniversity of Pittsburgh − Of the Commonwealth System of Higher Education | 薬剤を送達するための小型ポリマー担体 |
| CN110327300B (zh) * | 2019-07-23 | 2020-08-07 | 赵修文 | 一种负载药物的聚乙烯醇微球 |
| WO2022010850A1 (en) * | 2020-07-06 | 2022-01-13 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Polymeric carriers for delivery of therapeutic agents |
| WO2022047544A1 (en) * | 2020-09-04 | 2022-03-10 | IP Cornerstone Pty Ltd | Minimally invasive treatment of osteoarthritis and other conditions |
| US20240207256A1 (en) * | 2021-05-12 | 2024-06-27 | Neupharma, Inc | Certain chemical entities, compositions, and methods |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL409579A1 (pl) * | 2001-02-19 | 2015-03-02 | Novartis Ag | Leczenie raka |
| WO2003028696A2 (en) * | 2001-10-03 | 2003-04-10 | Celator Technologies Inc. | Compositions for delivery of drug combinations |
| US7850990B2 (en) * | 2001-10-03 | 2010-12-14 | Celator Pharmaceuticals, Inc. | Compositions for delivery of drug combinations |
| US20050220880A1 (en) * | 2002-03-07 | 2005-10-06 | Lewis Andrew L | Drug carriers comprising amphiphilic block copolymers |
| US20040161466A1 (en) * | 2003-02-14 | 2004-08-19 | Biocompatibles Uk Limited | Chemoembolisation |
| CN103393605B (zh) * | 2003-02-12 | 2018-05-29 | 生物相容英国有限公司 | 用于实体瘤的化学栓塞治疗的组合物 |
| US20040265368A1 (en) * | 2003-04-02 | 2004-12-30 | Lawrence Mayer | Combination compositions of camptothecins and fluoropyrimidines |
| US20070275991A1 (en) * | 2004-09-07 | 2007-11-29 | Biocompatibles Uk Limited | Drug Delivery From Embolic Agents |
| US8663673B2 (en) * | 2005-07-29 | 2014-03-04 | Surmodics, Inc. | Devices, articles, coatings, and methods for controlled active agent release or hemocompatibility |
-
2008
- 2008-08-18 JP JP2010520637A patent/JP2010536738A/ja active Pending
- 2008-08-18 TR TR2018/20076T patent/TR201820076T4/tr unknown
- 2008-08-18 WO PCT/GB2008/050722 patent/WO2009022190A1/en not_active Ceased
- 2008-08-18 ES ES08788693T patent/ES2706023T3/es active Active
- 2008-08-18 EP EP08788693.3A patent/EP2190409B9/en not_active Not-in-force
- 2008-08-18 US US12/672,031 patent/US20110229572A1/en not_active Abandoned
-
2014
- 2014-01-30 JP JP2014016185A patent/JP2014114307A/ja active Pending
-
2016
- 2016-06-08 JP JP2016114725A patent/JP2016216465A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| ES2706023T3 (es) | 2019-03-27 |
| JP2010536738A (ja) | 2010-12-02 |
| JP2016216465A (ja) | 2016-12-22 |
| EP2190409B9 (en) | 2019-03-06 |
| EP2190409A1 (en) | 2010-06-02 |
| US20110229572A1 (en) | 2011-09-22 |
| EP2190409B1 (en) | 2018-10-24 |
| JP2014114307A (ja) | 2014-06-26 |
| WO2009022190A1 (en) | 2009-02-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201820076T4 (tr) | İlaç kombinasyonlarının salımı. | |
| NZ601200A (en) | Pharmaceutical dosage forms comprising poly(epsilon-caprolactone) | |
| BR112015000320A2 (pt) | composições farmacêuticas dissuasivas de abuso, de liberação prolongada | |
| BR112013016772B8 (pt) | compostos, uso do composto e composição farmacêutica | |
| JP2008519047A5 (https=) | ||
| EP3064220A3 (en) | Compositions and methods for the treatment of infections and tumors | |
| BRPI0507683A8 (pt) | dose unitária de formulação farmacêutica com liberação controlada, seu processo de preparação e uso de um copolímero de poli(acrilato de etila, metacrilato de metila) neutro | |
| TR200806298A2 (tr) | Farmasötik formülasyon | |
| BRPI0910746B8 (pt) | agente de reticulação, conjugado de agente de ligação celular-fármaco, seu uso, composto e composição farmacêutica | |
| WO2014102613A3 (en) | Device for disposal and neutralization of pharmaceutical agents | |
| WO2006116565A3 (en) | Biodegradable peptide sustained release compositions containing porogens | |
| BRPI0819719B8 (pt) | compostos de inibição de dipeptidil peptidase-iv, métodos de preparação dos mesmos, e preparações farmacêuticas contendo os mesmos como agente ativo | |
| ZA200900929B (en) | Microparticles based on an amphiphilic copolymer and on active ingredient(s) with modified release and pharmaceutical formulations containing same | |
| BRPI0616078B8 (pt) | pó de uma formulação farmacêutica de polímero de amina, uso de tal pó e formulação em sachê para polímeros de amina | |
| AR082691A1 (es) | Terapia de combinacion, producto farmaceutico, kit y uso | |
| CL2009001267A1 (es) | Compuestos derivados de triciclos nitrogenados, con actividad antibacteriana; procedimiento de preparacion; composicion farmceutica que los comprende; para el tratamiento de la tuberculosis. | |
| PL1962815T3 (pl) | Zastosowanie błonotwórczych polimerów do pielęgnacji włosów z grupy poluretanów i zawierające te polimery preparaty i plastry farmaceutyczne | |
| WO2006089114A3 (en) | Methods and compositions for treating an anthrax toxin mediated condition | |
| WO2010073126A3 (en) | Compounds useful in delivering anti-neoplastic therapy and diagnostic imaging to hypoxic cells and methods of use thereof | |
| WO2012092486A3 (en) | Modified release benzimidazole formulations | |
| RU2007113156A (ru) | Твердая нанокомпозиция для доставки биологически активных веществ | |
| MX341642B (es) | Composicion de liberacion sostenida que contiene peptidos como ingredientes activos. | |
| MX2017010631A (es) | Composiciones de dialquil sulfosuccinato, metodos para hacerlas y metodos de uso. | |
| TR200806300A2 (tr) | Çözünürlük artırıcı farmasötlk formulasyon | |
| WO2006041538A3 (en) | A mixture for transdermal delivery of low and high molecular weight compounds |